We are pleased to announce that our company representatives will be attending the EANM 2025 Annual Congress in Barcelona, Spain. As one of the most significant global gatherings in nuclear medicine, EANM provides an excellent platform for collaboration, knowledge sharing, and showcasing advancements in diagnostic and therapeutic radiopharmaceuticals.

We invite delegates, partners, and industry professionals to connect with us during the conference. Our team will be available to discuss our expanding product portfolio—including I-131 formulations, 177Lu therapies, 99mTc solutions, F-18 radiopharmaceuticals, and our new medical cyclotron capabilities—as well as opportunities for partnership and future collaboration.

We look forward to meeting you in Barcelona and engaging with the global nuclear medicine community at EANM 2025.